Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. 

 -  2024 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>2041-1723 
<br/><br/><label>Standard No.: </label>10.1038/s41467-024-48359-1 [pii] PMC11087457 [pmc] 
<br/><br/><label>Subjects--Topical Terms: </label>--Automated
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Washington Hospital Center
<br/><br/><label>Index Terms--Occupation: </label><br/>Associate Dean for Research Development<br/>Hematology/Oncology<br/>MedStar Health
<br/><br/><label>Index Terms--Function: </label><br/>Published Erratum